PT  - JOURNAL ARTICLE
AU  - Romero-Ibarguengoitia, Maria Elena
AU  - González Cantú, Arnulfo
AU  - Hernández-Ruíz, Yodira Guadalupe
AU  - Amerndariz-Vázquez, Ana Gabriela
AU  - Rivera-Salinas, Diego
AU  - Montelongo-Cruz, Laura Patricia
AU  - del Río-Parra, Gerardo Francisco
AU  - Barco-Flores, Irene Antonieta
AU  - González-Facio, Rosalinda
AU  - Sanz-Sánchez, Miguel Ángel
TI  - Effect of heterologous vaccination regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG antibodies titers
AID  - 10.1101/2021.10.07.21264657
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.07.21264657
4099  - http://medrxiv.org/content/early/2021/10/11/2021.10.07.21264657.short
4100  - http://medrxiv.org/content/early/2021/10/11/2021.10.07.21264657.full
AB  - Introduction The efficacy with one dose Ad5-nCoV has been concerned. As a result, some patients have self-reported getting a boost with BNT. Therefore, this study aimed to compare SARS-CoV-2 spike 1-2 IgG antibodies in plasma samples between two groups: one group immunized with Ad5-nCoV and another with a heterologous vaccination regimen with Ad5-nCoV and BNT.Methods Prospective observational study included a subgroup analysis of patients who received the Ad5-nCoV immunization during the first trimester of 2021 in a Northern city of Mexico; and agreed to a follow-up for an entire year through SARS-CoV-2 specific IgG antibodies measurement samples. During the three months follow-up, some patients self-reported receiving a BNT boost. We report IgG levels from basal, 21-28 days after Ad5-nCoV dose, three months, and an additional 21-28 days after BNT boost.Results Seventeen patients 40 (16) years old, 52.9% men, were analyzed. We created four groups: (G1) patients vaccinated with Ad5-nCoV with no history of SARS-COV-2 (n=4), (G2) patients vaccinated with Ad5-nCoV and the first shot of BNT with no history of SARS-COV-2 (n=6), (G3) patients vaccinated with Ad5-nCoV with history of SARS-COV-2 (n=5), and (G4) patients vaccinated with Ad5-nCoV and the first shot of BNT with history of SARS-COV-2 (n=2).The group immunized with a heterologous vaccine scheme reported higher antibodies after 21-28 days of follow-up after BNT boost. Median (IQR): G1 46.7 (-), G2 1077.5 (1901), G3 1158.5 (2673.5), and G4 2090 (-) (p<0.05). Headache was the most frequent adverse reaction when patients received Ad5-nCoV (n = 10, 83%), and pain at the injection site was the most frequent adverse reaction with BNT boost (n = 5, 83.3%).Conclusion Patients receiving a BNT boost after Ad5-nCoV had higher SARS-CoV-2 spike 1-2 IgG antibodies titers with no severe adverse reaction.Author Approval all authors read an approved the final version of the manuscriptCompeting Interests The authors have declared no competing interestFunding The research was supported by private funding provided by the hospital. No external funding was used.Ethics statement Ethics committee/local Institutional Review Board from the school of Medicine from Universidad de Monterrey gave ethical approval: Ref.:26022021-CN-1e-CICompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNA since there was no experimental treatment to applyFunding StatementFunding was provided by private funds from the hospital where the study was developed. No external fundings were receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/local Institutional Review Board from the school of Medicine from Universidad de Monterrey gave ethical approval: Ref.:26022021-CN-1e-CII confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata available upon request